Collections
*** NOT USED, MERGED INTO NEURONTIN LITIGATION DOCUMENTS *** Consumers and third-party payers, including insurance companies and trade unions, sought repayment of billions of dollars paid for Neurontin prescriptions alleging Pfizer fraudulently misrepresented the drug's benefits. The plaintiffs argued the documents in this case revealed that even after the Neurontin settlement (see Franklin v Parke-Davis), Pfizer "continued with the medical marketing firms and planted marketing messages in journal articles (saying) that Neurontin was effective while they knew that their own clinical trials had failed to demonstrate it was effective."
